Prognostic factors in patients with soft palate squamous cell carcinoma

Abstract

Background To define the prognostic factors associated with outcome in patients with soft palate squamous cell carcinoma (SCC). Methods Previously untreated patients with soft palate and uvula SCC treated in our institution between 1997 and 2012 were collected. The prognostic value of clinical, hematological, and treatment characteristics was examined. Results We identified 156 patients, median age 58 years, with 71% drinkers, 91% smokers; 19% had synchronous cancer. Front‐line treatment was chemoradiotherapy in 58 (37%), radiotherapy alone in 60 (39%), surgery in 17 (11%), and induction chemotherapy in 21 patients (14%). The 5‐year actuarial overall survival (OS) and progression‐free survival (PFS) were 41% and 37%, respectively. In univariate analysis, T3‐T4 vs T1‐T2 stage, N2‐N3 vs N0‐N1 stage, and neutrophil count >7 g/L were associated with worse OS and PFS (P < .05). Conclusion In patients with soft palate SCC, inflammation biomarkers were associated with OS.

MAPKAPK2 (MK2) inhibition mediates radiation-induced inflammatory cytokine production and tumor growth in head and neck squamous cell carcinoma

“…Neutrophilia and increased neutrophil-to-lymphocyte ratios (NLR) are markers of inflammation and are shown to be associated with decreased overall survival in HNSCC [14][15][16]. Furthermore, high expression of downstream inflammatory cytokines is associated with worse overall survival in HNSCC [17,18].…”

Radiation treatment of soft palate squamous cell carcinoma

“…Other institutions have reported their experiences treating soft palate squamous cell carcinomas (Table 5). [7][8][9][10][11][12][13][14][15][16][17][18] Most prior studies report local control based on tumor stage but few provide stagestratified local-regional control rates or survival rates.…”

The Multiple Roles of CD147 in the Development and Progression of Oral Squamous Cell Carcinoma: An Overview

“…Besides mediating OSCC cell invasion of the peritumoral tissue, the concomitant activation of MMPs and uPA favors OSCC infiltration by stromal cells and leukocytes secreting cytokines and growth factors with a pro-tumor action [ 94 , 95 ]. However, MMPs and uPA can also facilitate the penetration of cancer tissues by immune cells endowed with antitumor activities [ 96 , 97 ].…”

“…Indeed, M2 macrophages release into the tumor microenvironment inflammatory cytokines and growth factors that inhibit anti-tumor immune responses or promote the proliferation of neoplastic cells [ 139 , 140 ]. Altogether, these findings explain why the number of neutrophils or macrophages that are present in OSCC tissues directly correlates with patients’ poor clinical outcomes [ 94 , 95 , 138 , 140 ].…”